Minirin (Desmopressin Acetate)

Desmopressin selectively binds to V2 receptors on renal collecting‑duct cells, stimulating the insertion of aquaporin‑2 water channels, which enhances water reabsorption and concentrates urine. In endothelial cells it triggers release of von Willebrand factor and factor VIII, improving haemostatic function.

The prescribed dose of Minirin is individualized by the treating clinician based on the specific indication, patient age, renal function and response. Dosing may be administered by intramuscular, intravenous or subcutaneous injection, and the prescriber determines the exact amount and frequency.

Safety data for desmopressin during pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used when clearly needed and after a risk‑benefit assessment by a healthcare professional. Caution is also advised during lactation; the drug may be excreted in breast milk.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with natural vasopressin, desmopressin has a longer half‑life, greater selectivity for V2 receptors and reduced vasoconstrictive activity, resulting in fewer cardiovascular side effects. It is also more potent than oral antidiuretic agents such as carbamazepine, allowing lower dosing and more predictable water‑retaining effects.

Minirin injectable solution must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect from light, and avoid freezing or shaking. If a short period at room temperature is unavoidable, limit exposure to no more than 24 hours before use.

Minirin is supplied as a sterile injectable solution and can be given by intramuscular, intravenous or subcutaneous injection. Administration follows standard aseptic techniques; the exact route, volume and injection site are selected by the prescriber according to the clinical situation.

The most serious adverse events linked to desmopressin are severe hyponatraemia, which can lead to seizures, cerebral oedema or coma, and allergic reactions including anaphylaxis. Patients should be monitored for rapid weight gain, low serum sodium and any signs of hypersensitivity.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin or its excipients, in patients with uncontrolled hyponatraemia, severe renal impairment, or uncontrolled heart failure where fluid overload is a risk. Caution is also advised for those with a history of epilepsy or adrenal insufficiency.